acyclovir

(redirected from Xerese)
Also found in: Thesaurus, Medical.
Related to Xerese: XERXES

a·cy·clo·vir

 (ā-sī′klō-vîr, -klə-)
n.
A synthetic purine nucleoside analog, C8H10N5O3, derived from guanine and used in the treatment of herpes simplex, herpes zoster, and varicella-zoster virus infections.

[acyclo(guanosine) (a- + cyclo- + guanosine) + (anti)vir(al).]

acyclovir

(eɪˈsaɪkləʊˌvɪə)
n
an antiviral drug used to treat herpes. Formula: C8H11N5O3

a•cy•clo•vir

(eɪˈsaɪ kloʊˌvɪər, -klə-)

n.
a synthetic crystalline compound, C18H11N5O3, used as an antiviral drug in the treatment of herpes infections.
[1980–85]
ThesaurusAntonymsRelated WordsSynonymsLegend:
Noun1.acyclovir - an oral antiviral drug (trade name Zovirax) used to treat genital herpesacyclovir - an oral antiviral drug (trade name Zovirax) used to treat genital herpes; does not cure the disease but relieves the symptoms
medicament, medication, medicinal drug, medicine - (medicine) something that treats or prevents or alleviates the symptoms of disease
Translations

acyclovir

n aciclovir m
References in periodicals archive ?
During the second quarter of 2011, Medivir received USD45m from Meda AB (STO:MEDA A), which acquired the American rights to cold sore treatment Xerese.
30 June 2011 - Swedish pharma company Meda AB (STO: MEDA A) said today it has licenced to Canada-based Valeant Pharmaceuticals Intl Inc (NYSE: VRX) (TSX: VRX) the exclusive rights for the Elidel and Xerese creams for the USA, Canada and Mexico.
29 June 2011 - Sweden-based pharmaceutical company Medivir AB (STO: MVIR) announced today that it has renegotiated the terms of its commercial partnership with Meda (STO: MEDA A) for Xerese, its unique marketed product for cold sores (herpes labialis).
M2 EQUITYBITES-June 30, 2011-Valeant Pharmaceuticals licenses North American rights of Elidel and Xerese from Meda(C)2011 M2 COMMUNICATIONS http://www.
29 June 2011 - Swedish pharma company Meda AB (STO: MEDA A) received all the rights to Xerese, a product for cold sores, in North America from partner Medivir AB (STO: MVIR B) for USD45m, the firms said today.
M2 PHARMA-March 1, 2011-Meda launches Medivir's Xerese in USA(C)2011 M2 COMMUNICATIONS
st), a research-based specialty pharmaceutical company focused on infectious diseases, today announced that it has renegotiated the terms of its commercial partnership with Meda (OMX: MEDA A), a specialty pharmaceutical company, for Xerese, Medivir's unique marketed product for cold sores (herpes labialis).
1 March 2011 - Swedish pharma company Medivir AB (STO: MVIR B) said today its cold sore treatment Xerese had been launched in the USA by partner Meda AB (STO: MEDA A).